SG11202003635TA - Crystalline salts of a b-raf kinase inhibitor - Google Patents
Crystalline salts of a b-raf kinase inhibitorInfo
- Publication number
- SG11202003635TA SG11202003635TA SG11202003635TA SG11202003635TA SG11202003635TA SG 11202003635T A SG11202003635T A SG 11202003635TA SG 11202003635T A SG11202003635T A SG 11202003635TA SG 11202003635T A SG11202003635T A SG 11202003635TA SG 11202003635T A SG11202003635T A SG 11202003635TA
- Authority
- SG
- Singapore
- Prior art keywords
- kinase inhibitor
- raf kinase
- crystalline salts
- crystalline
- salts
- Prior art date
Links
- 229940102297 B-raf kinase inhibitor Drugs 0.000 title 1
- 239000002774 b raf kinase inhibitor Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762577313P | 2017-10-26 | 2017-10-26 | |
| PCT/US2018/057792 WO2019084459A1 (en) | 2017-10-26 | 2018-10-26 | Crystalline salts of a b-raf kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202003635TA true SG11202003635TA (en) | 2020-05-28 |
Family
ID=64277870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202003635TA SG11202003635TA (en) | 2017-10-26 | 2018-10-26 | Crystalline salts of a b-raf kinase inhibitor |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11306086B2 (en) |
| EP (2) | EP3700530B1 (en) |
| JP (2) | JP7230041B2 (en) |
| KR (1) | KR20200088345A (en) |
| CN (2) | CN111818924B (en) |
| AU (2) | AU2018355528B2 (en) |
| BR (1) | BR112020008248A2 (en) |
| CA (1) | CA3080324A1 (en) |
| ES (1) | ES2947411T3 (en) |
| IL (1) | IL274027B2 (en) |
| MX (1) | MX2020004148A (en) |
| PH (1) | PH12020550485A1 (en) |
| SG (1) | SG11202003635TA (en) |
| WO (1) | WO2019084459A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3700530B1 (en) | 2017-10-26 | 2023-04-19 | Xynomic Pharmaceuticals, Inc. | Crystalline salts of a b-raf kinase inhibitor |
| JP2022069426A (en) * | 2020-10-23 | 2022-05-11 | マイラン ラボラトリーズ リミテッド | Method of preparing amorphous teneligliptin 2.5 hydrobromide |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1294358E (en) | 2000-06-28 | 2004-12-31 | Smithkline Beecham Plc | MOORING PROCESS BY HUMIDITY |
| JP2007511596A (en) * | 2003-11-17 | 2007-05-10 | ファイザー・プロダクツ・インク | Pyrrolopyrimidine compounds useful in the treatment of cancer |
| GB0423554D0 (en) * | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| DK1893612T3 (en) | 2005-06-22 | 2011-11-21 | Plexxikon Inc | Pyrrole [2,3-B] pyridine derivatives as protein kinase inhibitors |
| US7501430B2 (en) * | 2006-04-17 | 2009-03-10 | Arqule, Inc. | RAF inhibitors and their uses |
| EP1914234A1 (en) * | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
| WO2010042337A1 (en) | 2008-10-07 | 2010-04-15 | Merck Sharp & Dohme Corp. | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
| ES2570569T3 (en) * | 2009-09-28 | 2016-05-19 | Hoffmann La Roche | Benzoxazepine compounds as PI3K inhibitors and methods of use |
| US8889684B2 (en) | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| JP6263469B2 (en) | 2011-07-15 | 2018-01-17 | ノバルティス アーゲー | Salt of azabicyclic di-aryl ether and method for producing the same or method for producing the precursor |
| RU2760835C2 (en) | 2015-04-16 | 2021-11-30 | Нитто Денко Корпорейшн | Agent inducing cell death for cells having braf gene mutations, agent suppressing growth of such cells, and pharmaceutical composition for the therapy of diseases caused by growth defect of such cells |
| CN105801584B (en) * | 2016-03-16 | 2019-03-05 | 中国药科大学 | Novel aryl amide Raf kinase and its preparation method and application |
| EP3700530B1 (en) | 2017-10-26 | 2023-04-19 | Xynomic Pharmaceuticals, Inc. | Crystalline salts of a b-raf kinase inhibitor |
-
2018
- 2018-10-26 EP EP18801183.7A patent/EP3700530B1/en active Active
- 2018-10-26 AU AU2018355528A patent/AU2018355528B2/en active Active
- 2018-10-26 CA CA3080324A patent/CA3080324A1/en active Pending
- 2018-10-26 BR BR112020008248-1A patent/BR112020008248A2/en unknown
- 2018-10-26 MX MX2020004148A patent/MX2020004148A/en unknown
- 2018-10-26 CN CN201880081003.9A patent/CN111818924B/en active Active
- 2018-10-26 CN CN202310913355.9A patent/CN116942672A/en active Pending
- 2018-10-26 IL IL274027A patent/IL274027B2/en unknown
- 2018-10-26 WO PCT/US2018/057792 patent/WO2019084459A1/en unknown
- 2018-10-26 JP JP2020543248A patent/JP7230041B2/en active Active
- 2018-10-26 KR KR1020207014962A patent/KR20200088345A/en not_active Application Discontinuation
- 2018-10-26 EP EP23167989.5A patent/EP4245758A3/en active Pending
- 2018-10-26 US US16/759,187 patent/US11306086B2/en active Active
- 2018-10-26 SG SG11202003635TA patent/SG11202003635TA/en unknown
- 2018-10-26 ES ES18801183T patent/ES2947411T3/en active Active
-
2020
- 2020-04-24 PH PH12020550485A patent/PH12020550485A1/en unknown
-
2022
- 2022-02-17 AU AU2022201044A patent/AU2022201044B2/en active Active
- 2022-03-11 US US17/692,695 patent/US11753409B2/en active Active
-
2023
- 2023-02-15 JP JP2023021816A patent/JP2023062074A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4245758A3 (en) | 2023-12-20 |
| CN116942672A (en) | 2023-10-27 |
| IL274027B2 (en) | 2023-12-01 |
| CA3080324A1 (en) | 2019-05-02 |
| RU2020116763A3 (en) | 2022-04-29 |
| CN111818924B (en) | 2023-08-15 |
| EP3700530B1 (en) | 2023-04-19 |
| AU2018355528B2 (en) | 2021-11-18 |
| AU2018355528A1 (en) | 2020-05-07 |
| RU2020116763A (en) | 2021-11-26 |
| AU2022201044B2 (en) | 2023-07-13 |
| JP2021501199A (en) | 2021-01-14 |
| US11306086B2 (en) | 2022-04-19 |
| WO2019084459A1 (en) | 2019-05-02 |
| PH12020550485A1 (en) | 2021-03-22 |
| US11753409B2 (en) | 2023-09-12 |
| US20220204506A1 (en) | 2022-06-30 |
| BR112020008248A2 (en) | 2020-10-20 |
| MX2020004148A (en) | 2022-09-09 |
| JP2023062074A (en) | 2023-05-02 |
| AU2022201044A1 (en) | 2022-03-10 |
| CN111818924A (en) | 2020-10-23 |
| US20200283433A1 (en) | 2020-09-10 |
| EP4245758A2 (en) | 2023-09-20 |
| KR20200088345A (en) | 2020-07-22 |
| EP3700530A1 (en) | 2020-09-02 |
| JP7230041B2 (en) | 2023-02-28 |
| IL274027B1 (en) | 2023-08-01 |
| ES2947411T3 (en) | 2023-08-08 |
| IL274027A (en) | 2020-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259719A (en) | Tank-binding kinase inhibitor compounds | |
| IL287740A (en) | Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore | |
| ZA201903093B (en) | Crystalline forms of a magl inhibitor | |
| IL285686B (en) | Crystalline solid forms of a bet inhibitor | |
| HK1256806A1 (en) | Salts of a pim kinase inhibitor | |
| IL283860A (en) | Crystalline forms and salt forms of a kinase inhibitor | |
| IL288484A (en) | Crystalline salt forms of a kinase inhibitor | |
| IL267393A (en) | Crystalline forms of a janus kinase inhibitor | |
| EP3193874A4 (en) | Crystalline forms of tyrosine kinase inhibitors and their salts | |
| IL274027A (en) | Crystalline salts of a b-raf kinase inhibitor | |
| IL272835A (en) | The salts of a compound and the crystalline forms thereof | |
| HK1252841A1 (en) | Crystalline forms of hydrochloride salts of thienopyrimidine compound | |
| GB201807845D0 (en) | Kinase Inhibitors | |
| SG11202105355XA (en) | Crystalline salts of corydalmine | |
| HK1244006A1 (en) | Crystalline forms of parp inhibitors | |
| HK1243420A1 (en) | Novel crystalline form of a proteasome inhibitor |